| Paroxysmal nocturnal hemoglobinuria
Fabhalta vs Ultomiris
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Fabhalta vs Ultomiris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltomiris has a higher rate of injection site reactions vs Fabhalta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultomiris but not Fabhalta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fabhalta
Ultomiris
At A Glance
Oral
Twice daily
Factor B inhibitor
IV infusion
Every 4-8 weeks
C5 complement inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Contraindications
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Pharmacology
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultomiris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FabhaltaView full Fabhalta profile
UltomirisView full Ultomiris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.